Key facts
- This page summarizes Lance Baldo's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Mar 2022, 17:00.
Lance Baldo - 08 Mar 2022 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ADPT
- Reported as of
- 08 Mar 2022
- Net transaction value
- -$38,290
- SEC form
- 4
- Accepted by SEC
- 10 Mar 2022, 17:00:16 UTC
- Prior SEC filing
- 08 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lance Baldo by Eric Billings, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lance Baldo filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 10 Mar 2022.
Change
- Previous filing in this sequence was filed on 08 Mar 2022.
- Current net transaction value: -$38,290.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADPT
transaction
Common Stock
Sale
- Transaction value
- $38,290
- Shares
- -3,350
- Change %
- -16%
- Price
- $11.43
- Shares after
- 17,171
- Date
- 08 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021.
Footnote F2
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.28 to 11.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.